ALX Oncology Stock Price, News & Analysis (NASDAQ:ALXO) $12.26 +3.01 (+32.54%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$10.15▼$13.5050-Day Range$4.81▼$12.2652-Week Range$3.94▼$13.50Volume3.85 million shsAverage Volume535,468 shsMarket Capitalization$610.78 millionP/E RatioN/ADividend YieldN/APrice Target$20.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media ALX Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.7% Upside$20.07 Price TargetShort InterestBearish17.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.61) to ($3.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector310th out of 945 stocksPharmaceutical Preparations Industry106th out of 423 stocks 4.5 Analyst's Opinion Consensus RatingALX Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.07, ALX Oncology has a forecasted upside of 63.7% from its current price of $12.26.Amount of Analyst CoverageALX Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.50% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ALX Oncology has recently increased by 2.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALXO. Previous Next 2.0 News and Social Media Coverage News SentimentALX Oncology has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ALX Oncology this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders50.30% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.37% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ALX Oncology are expected to grow in the coming year, from ($3.61) to ($3.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ALX Oncology Stock (NASDAQ:ALXO)ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More ALXO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALXO Stock News HeadlinesDecember 9, 2023 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Upgraded to "Buy" at Jefferies Financial GroupDecember 9, 2023 | msn.comJefferies Upgrades Alx Oncology Holdings (ALXO)December 9, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 8, 2023 | msn.comJefferies raises ALX Oncology to buy, cites upcoming catalystsDecember 8, 2023 | msn.comALX Oncology shares jump 9% after Jefferies upgradeNovember 30, 2023 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) and Keros Therapeutics (NASDAQ:KROS) Head-To-Head ComparisonNovember 15, 2023 | markets.businessinsider.comPromising Interim Data and Financial Stability Prompt Buy Rating for ALX Oncology HoldingsNovember 13, 2023 | finance.yahoo.comALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 13, 2023 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate DevelopmentsNovember 1, 2023 | finance.yahoo.comALX Oncology Announces November Investor Conference ParticipationOctober 12, 2023 | fool.comALX Oncology (NASDAQ: ALXO)October 11, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on ALX Oncology Holdings (ALXO)October 10, 2023 | finance.yahoo.comALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesOctober 9, 2023 | finance.yahoo.comWhile institutions invested in ALX Oncology Holdings Inc. (NASDAQ:ALXO) benefited from last week's 74% gain, private equity firms stood to gain the mostOctober 9, 2023 | msn.comALX Oncology: On Right Track With Latest Interim Analysis Of EvorpaceptOctober 6, 2023 | msn.comAlx Oncology Holdings (ALXO) Price Target Increased by 13.11% to 16.98October 5, 2023 | benzinga.comWhat's Going On With ALX Oncology Stock?October 5, 2023 | finance.yahoo.comBiotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & MoreOctober 5, 2023 | finance.yahoo.comALX Oncology Announces Pricing of Public OfferingOctober 4, 2023 | finance.yahoo.comALX Oncology Announces Proposed Public OfferingOctober 4, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for ALX Oncology HoldingsOctober 3, 2023 | proactiveinvestors.comALX Oncology stock doubles on early data from phase II cancer trialOctober 3, 2023 | msn.comWhy Cancer-Focused ALX Oncology Stock Gained Over 100% Today?October 3, 2023 | finance.yahoo.comPoint Biopharma, ALX Oncology surge premarket; McCormick, Airbnb fallsOctober 3, 2023 | finance.yahoo.comWhy ALX Oncology Stock Is Skyrocketing TodayOctober 3, 2023 | msn.comBiggest stock movers today: ALX Oncology Holdings, Sibanye Stillwater and moreSee More Headlines Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALXO CUSIPN/A CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees71Year FoundedN/APrice Target and Rating Average Stock Price Target$20.07 High Stock Price Target$34.00 Low Stock Price Target$10.00 Potential Upside/Downside+66.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.07% Return on Assets-53.14% Debt Debt-to-Equity Ratio0.06 Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual Sales$1.18 million Price / Sales517.61 Cash FlowN/A Price / Cash FlowN/A Book Value$6.46 per share Price / Book1.90Miscellaneous Outstanding Shares49,819,000Free Float24,760,000Market Cap$610.78 million OptionableNot Optionable Beta1.39 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Corey S. Goodman Ph.D. (Age 71)Executive Chairman Comp: $84kMr. Jason W. Lettmann (Age 46)CEO & Director Comp: $60.5kDr. Jaume Pons Ph.D. (Age 57)Founder, President, Director & Chief Scientific Officer Comp: $856.29kMr. Peter S. Garcia M.B.A. (Age 61)Chief Financial Officer Comp: $631.11kDr. Sophia Randolph M.D. (Age 55)Ph.D., Chief Medical Officer & Director Comp: $637.24kDr. Michael Chang Ph.D.Vice President of OperationsMs. Shelly Pinto (Age 47)Senior VP of Finance & Chief Accounting Officer Comp: $508.26kDr. Christopher Byrd J.D.Ph.D., General CounselDr. Athanasios Tsiatis M.D.Senior Vice President of Clinical DevelopmentDr. Lin Yeong-Liang M.D.M.S., Senior Vice President of Drug Safety & PharmacovigilanceMore ExecutivesKey CompetitorsTerns PharmaceuticalsNASDAQ:TERNEdgewise TherapeuticsNASDAQ:EWTXSIGA TechnologiesNASDAQ:SIGAOculisNASDAQ:OCSAdlai NortyeNASDAQ:ANLView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 10,257 shares on 11/30/2023Ownership: 0.021%Trexquant Investment LPSold 36,162 shares on 11/14/2023Ownership: 0.035%FMR LLCSold 538,592 shares on 11/13/2023Ownership: 13.589%Federated Hermes Inc.Sold 3,610 shares on 11/13/2023Ownership: 0.611%Hsbc Holdings PLCBought 35,404 shares on 11/13/2023Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions ALXO Stock Analysis - Frequently Asked Questions Should I buy or sell ALX Oncology stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks. What is ALX Oncology's stock price target for 2024? 8 Wall Street research analysts have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they predict the company's stock price to reach $20.07 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts. How have ALXO shares performed in 2023? ALX Oncology's stock was trading at $11.27 on January 1st, 2023. Since then, ALXO stock has increased by 8.8% and is now trading at $12.26. View the best growth stocks for 2023 here. When is ALX Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our ALXO earnings forecast. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its quarterly earnings data on Monday, November, 13th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.38. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did ALX Oncology IPO? (ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are ALX Oncology's major shareholders? ALX Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (13.59%), Federated Hermes Inc. (0.61%), Charles Schwab Investment Management Inc. (0.34%), Hsbc Holdings PLC (0.09%), Barclays PLC (0.07%) and J.P. Morgan Private Wealth Advisors LLC (0.05%). Insiders that own company stock include G Walmsley Graham, Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph. View institutional ownership trends. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ALXO) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.